Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch
23.4.2026 11:00:00 EEST | Business Wire | Press release
Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the expansion of the firm’s evergreen offering. The launch of PGIS now cements Pantheon’s global evergreen offerings across private equity, private credit secondaries, and infrastructure secondaries and complements its existing international evergreen suite alongside Pantheon Global Private Equity (PGPE), and Pantheon Global Credit Secondaries Fund (PGCS).
PGIS aims to comprise a high-conviction portfolio and is designed to provide professional investors with access to a diversified portfolio of global infrastructure secondaries assets, managed by the firm’s distinguished institutional infrastructure arm. Jérôme Duthu-Bengtzon, Partner and Portfolio Manager of PGIS, said, “The new fund will aim to combine the benefits of infrastructure investments, including the potential for capital appreciation, yield, lower volatility, and portfolio diversification, with the added advantages of secondaries, which can offer greater risk mitigation, diversification, shorter investment durations, and more immediate distributions compared to traditional infrastructure investments.”4
The launch of PGIS reflects growing demand for Pantheon’s global infrastructure strategy and in particular its concentrated focus and established expertise in infrastructure secondaries, which have come more into focus in the current market environment amid heightened demand for liquidity from both investors and fund managers.
PGIS sources expertise from Pantheon’s private infrastructure secondaries strategy
Pantheon has been investing in private markets secondaries since 1988 and was one of the first fund managers globally to recognize the potential of infrastructure secondaries, raising its first fund including the strategy in 2010. Since then, the firm has raised four infrastructure funds with an increasing focus on secondaries,5 completing its largest ever infrastructure program fundraise in 2024 with commitments totaling $5.3bn, and now manages $26.9 billion6 in total discretionary assets under management in infrastructure globally.
Andrea Echberg, Global Head of Infrastructure, said, “As true infrastructure investors—not generalists—we’re scaling with precision to power the future of global infrastructure secondaries. Delivering this expertise to the private wealth market is the next step in our firm’s evolution. We are an infrastructure-first, secondaries investor, with 35 specialists managing one of the world’s largest dedicated platforms. We combine asset-level expertise with valuation discipline, focusing on digital, renewable, and next-generation infrastructure.”
Victor Mayer, Head of International in Pantheon’s Global Private Wealth team, added, “The launch of our infrastructure secondaries strategy marks a significant milestone for Pantheon's evergreen platform. The fund launch is a strategic step in the careful build-out of a comprehensive offering now spanning private equity, private credit, and private infrastructure across our global product suite. This reinforces our commitment to providing clients and allocators worldwide with differentiated access to compelling mid-market secondary and co-investment opportunities across Pantheon's global investment capabilities.”
About Pantheon
Pantheon* has been at the forefront of private markets investing for more than 40 years, earning a reputation for providing innovative solutions covering the full lifecycle of investments, from primary fund commitments to co-investments and secondary purchases, across private equity, private credit, and real assets. For more information, please visit www.pantheon.com.
We have partnered globally with institutional investors of all sizes as well as a growing number of private wealth advisers and investors, with approximately $85bn in discretionary assets under management (as of September 30, 2025).
Leveraging our specialized experience and global team of professionals across Europe, the Americas, and Asia, we invest with purpose and lead with expertise to build secure financial futures.
* Pantheon refers to the subsidiaries and subsidiary undertakings of Pantheon Ventures Inc. and AMG Plymouth UK Holdings Limited and includes operating entities principally based in the US (San Francisco and New York), UK (London), Hong Kong, Guernsey, Tokyo, Dublin and Singapore. Pantheon Ventures Inc. and Pantheon Ventures (US) LP are registered as investment advisors with the US Securities and Exchange Commission (“SEC”); Pantheon Securities, LLC is a broker dealer registered with the SEC and is a member of the Financial Industry Regulatory Authority (“FINRA”). Pantheon Ventures (UK) LLP is authorized and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom. Pantheon Ventures (Guernsey) Ltd and a number of other Pantheon entities incorporated in Guernsey are regulated by the Guernsey Financial Services Commission. Pantheon Ventures (Asia) Limited is registered as a Type II Financial Instruments Business and Investment Advisory and Agency Business Operator with the Kanto Local Finance Bureau in Japan (KLFB). Pantheon Ventures (Ireland) DAC is regulated by the Central Bank of Ireland (“CBI”) and is an appointed representative of Pantheon Ventures (UK) LLP in respect of activities carried out in the United Kingdom. Pantheon Ventures (Singapore) Pte. Ltd holds a capital markets service license from the Monetary Authority of Singapore (“MAS”) to conduct fund management with accredited and institutional investors.
This press release is not an offer of securities for sale. Securities may not be offered or sold in the United States absent registration or an exemption from registration. © 2026
This is a marketing communication, please refer to the Prospectus before making any final investment decision.
Pantheon opinion. Past performance is not indicative of future results. Future results are not guaranteed, and a loss of principal may occur. |
1 As of September 30, 2025. |
2 Pantheon Internal Data, September 30 2025. *Evergreen includes evergreen and listed vehicles. |
3 PGIS is not available to investors in the US. |
4 There is no guarantee this investment approach will come to fruition. |
5 Funds included a range of approaches, including co-investments. |
6 As of September 30, 2025. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260422539502/en/
Contacts
For further information, please contact:
Pantheon
Mariella Reason, Pantheon Communications
Tel: +44 20 3473 3975 | Email: mariella.reason@pantheon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease2.5.2026 00:28:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury, Chief Executive Officer, Incyte. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 19:08:00 EEST | Press release
A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines were switched off and everyday life took center stage. The night also celebrated the start of the new partnership between Barilla and the Visa Cash App Racing Bulls (VCARB) Formula 1® Team, a meeting of
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 13:07:00 EEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 02:17:00 EEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors1.5.2026 00:16:00 EEST | Press release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom